Sec Form 3 Filing - Dahowski Diane @ BIO-RAD LABORATORIES, INC. - 2022-04-27

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Dahowski Diane 2. Issuer Name and Ticker or Trading Symbol BIO-RAD LABORATORIES, INC. [ BIO BIOB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) EVP, Global Supply Chain (Last) (First) (Middle) C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 04/27/2022 (Street) HERCULES, CA94547 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Bio-Rad A Common Stock 9,007.964 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units $ 0( 6 ) ( 1 ) ( 1 ) Bio-Rad A Common Stock 600 D Restricted Stock Units $ 0( 6 ) ( 2 ) ( 2 ) Bio-Rad A Common Stock 1,200 D Restricted Stock Units $ 0( 6 ) ( 3 ) ( 3 ) Bio-Rad A Common Stock 1,485 D Restricted Stock Units $ 0( 6 ) ( 4 ) ( 4 ) Bio-Rad A Common Stock 1,083 D Restricted Stock Units $ 0( 6 ) ( 5 ) ( 5 ) Bio-Rad A Common Stock 1,317 D Non-Qualified Stock Option (right to buy) $ 524.3 ( 7 ) 09/02/2030 Bio-Rad A Common Stock 1,444 D Non-Qualified Stock Option (right to buy) $ 814.95 ( 8 ) 09/01/2031 Bio-Rad A Common Stock 1,317 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Dahowski Diane C/O BIO-RAD LABORATORIES, INC. 1000 ALFRED NOBEL DRIVE HERCULES, CA94547 EVP, Global Supply Chain Signatures /s/ Diane Dahowski 05/06/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. ( 2 )On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. ( 3 )On September 3, 2019, the reporting person was granted 2,475 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. ( 4 )On September 2, 2020, the reporting person was granted 1,444 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. ( 5 )On September 1, 2021, the reporting person was granted 1,317 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. ( 6 )Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. ( 7 )The option, representing a right to purchase a total of 1,444 shares, becomes exercisable in four equal annual installments beginning on September 2, 2021, which is the first anniversary of the date on which the option was granted. ( 8 )The option, representing a right to purchase a total of 1,317 shares, becomes exercisable in four equal annual installments beginning on September 1, 2022, which is the first anniversary of the date on which the option was granted.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.